Try our beta test site
228 studies found for:    "methodist hospital" | Open Studies | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Single Dose rATG for Renal Allograft Rejection
Condition: Acute (Cellular) Renal Allograft Rejection
Intervention: Drug: rATG
2 Recruiting Hemodialysis in the Elderly (70yrs & Older)
Conditions: Kidney Disease;   Kidney Failure;   Chronic Kidney Disease
Interventions: Procedure: Surgical fistula creation from patient's anatomy;   Device: Surgical Graft implant
3 Recruiting Prospective Cohort of Transitional Urology Patients
Conditions: Spina Bifida;   Myelomeningocele;   Meningocele;   Bladder Exstrophy;   Genitourinary Congenital Anomalies;   Cloacal Exstrophy
Intervention:
4 Recruiting TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: TDM1;   Drug: Lapatinib;   Drug: Abraxane
5 Recruiting Reducing Radioisotope Dose: the Half-Dose CZT Study
Condition: Coronary Artery Disease
Intervention: Other: Half-dose isotope for NuclearStressTest
6 Recruiting Ciprofloxacin for Prevention of BK Infection
Condition: BK Virus Infection
Interventions: Drug: Ciprofloxacin;   Drug: placebo
7 Recruiting L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
Condition: Metastatic Triple Negative Breast Cancer
Interventions: Drug: L-NMMA;   Drug: Docetaxel;   Drug: Amlodipine;   Drug: Pegfilgrastim
8 Recruiting Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Hydroxytyrosol
9 Recruiting Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline (CAT)
Conditions: Breast Neoplasms;   Breast Cancer
Interventions: Drug: Taxane;   Drug: Taxotere;   Drug: Abraxane;   Drug: Ixabepilone
10 Recruiting TUMOR-ASSOCIATED ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR MULTIPLE MYELOMA
Condition: Multiple Myeloma
Intervention: Biological: TAA-specific CTLs
11 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel;   Drug: Pertuzumab
12 Recruiting HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
13 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
14 Recruiting Multi-scale Modeling of Breast Conserving Therapy
Condition: Breast Cancer
Intervention: Other: Standard of Care
15 Not yet recruiting Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Conditions: CD30-positive Lymphoma;   CD30-positive Solid Tumor
Interventions: Drug: Brentuximab Vedotin;   Drug: Alsertib
16 Not yet recruiting TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Condition: Estrogen Receptor Positive Breast Cancer
Interventions: Drug: TAK-228;   Drug: Tamoxifen
17 Recruiting Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma
Conditions: Lung Squamous Cell Carcinoma Stage IV;   Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions: Biological: ADV/HSV-tk;   Drug: Valacyclovir;   Radiation: SBRT;   Drug: nivolumab
18 Recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Interventions: Genetic: DNR.NPC-specific T cells;   Genetic: DNR.NPC-specific T cells + cyclophosphamide + fludarabine
19 Recruiting T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
Condition: Glioblastoma
Intervention: Genetic: HER2-specific T cells
20 Not yet recruiting Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
Condition: Hepatocellular Carcinoma
Interventions: Genetic: GLYCAR T cells;   Drug: Cytoxan;   Drug: Fludarabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.